Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported total revenues of $13,117.2 million for the year ended December 31, 2023, an increase of approximately 7.8% compared to the prior year. This growth was primarily driven by strong performance in Dupixent and the launch of EYLEA HD. Net income for the year was $3,953.6 million, resulting in diluted earnings per share of $34.77. The company continues to invest heavily in research and development, with expenses increasing to $4,439.0 million, reflecting progress across its diverse pipeline of product candidates in various therapeutic areas, including ophthalmology, immunology, oncology, and rare diseases. Regeneron maintains a robust financial position, with significant cash and marketable securities, and is actively managing its capital structure through share repurchases.
Financial Highlights
49 data points| Revenue | $13.12B |
| R&D Expenses | $4.44B |
| SG&A Expenses | $2.63B |
| Operating Expenses | $9.07B |
| Operating Income | $4.05B |
| Interest Expense | $73.00M |
| Net Income | $3.95B |
| EPS (Basic) | $37.05 |
| EPS (Diluted) | $34.77 |
| Shares Outstanding (Basic) | 106.70M |
| Shares Outstanding (Diluted) | 113.70M |
Key Highlights
- 1Total revenues increased by 7.8% to $13,117.2 million in 2023, driven by Dupixent and the launch of EYLEA HD.
- 2Net income was $3,953.6 million, with diluted EPS of $34.77.
- 3Research and development expenses increased by 23.5% to $4,439.0 million, underscoring continued investment in pipeline advancement.
- 4The company's substantial cash and marketable securities position provides financial flexibility.
- 5EYLEA and EYLEA HD revenues in the U.S. saw a slight decrease of 6% in 2023, impacted by the transition to EYLEA HD.
- 6Dupixent continues to show strong growth, with Regeneron's share of profits increasing significantly due to higher sales.
- 7Regeneron is progressing on multiple late-stage clinical candidates and has a broad preclinical portfolio, indicating future growth potential.